JP4267693B2 - インターフェロン抑圧による細胞培養でのウィルスワクチン製造強化方法 - Google Patents

インターフェロン抑圧による細胞培養でのウィルスワクチン製造強化方法 Download PDF

Info

Publication number
JP4267693B2
JP4267693B2 JP51050897A JP51050897A JP4267693B2 JP 4267693 B2 JP4267693 B2 JP 4267693B2 JP 51050897 A JP51050897 A JP 51050897A JP 51050897 A JP51050897 A JP 51050897A JP 4267693 B2 JP4267693 B2 JP 4267693B2
Authority
JP
Japan
Prior art keywords
virus
pkr
cells
cell
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP51050897A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11514344A (ja
JPH11514344A5 (enExample
Inventor
ロウ、アラン、エス．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of JPH11514344A publication Critical patent/JPH11514344A/ja
Publication of JPH11514344A5 publication Critical patent/JPH11514344A5/ja
Application granted granted Critical
Publication of JP4267693B2 publication Critical patent/JP4267693B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32051—Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP51050897A 1995-08-22 1996-08-22 インターフェロン抑圧による細胞培養でのウィルスワクチン製造強化方法 Expired - Lifetime JP4267693B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US262195P 1995-08-22 1995-08-22
US60/002,621 1995-08-22
PCT/US1996/013745 WO1997008292A1 (en) 1995-08-22 1996-08-22 Methods for enhancing the production of viral vaccines in cell culture by interferon suppression

Publications (3)

Publication Number Publication Date
JPH11514344A JPH11514344A (ja) 1999-12-07
JPH11514344A5 JPH11514344A5 (enExample) 2004-09-09
JP4267693B2 true JP4267693B2 (ja) 2009-05-27

Family

ID=21701659

Family Applications (2)

Application Number Title Priority Date Filing Date
JP51050897A Expired - Lifetime JP4267693B2 (ja) 1995-08-22 1996-08-22 インターフェロン抑圧による細胞培養でのウィルスワクチン製造強化方法
JP51045097A Expired - Fee Related JP3432519B2 (ja) 1995-08-22 1996-08-22 細胞培養でインターフェロン産生を高める方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP51045097A Expired - Fee Related JP3432519B2 (ja) 1995-08-22 1996-08-22 細胞培養でインターフェロン産生を高める方法

Country Status (10)

Country Link
US (6) US5840565A (enExample)
EP (2) EP0846160B1 (enExample)
JP (2) JP4267693B2 (enExample)
CN (1) CN1161469C (enExample)
AT (1) ATE289348T1 (enExample)
AU (2) AU707130B2 (enExample)
BR (1) BR9610550A (enExample)
CA (2) CA2229405C (enExample)
DE (1) DE69634360T2 (enExample)
WO (2) WO1997008324A1 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855519B2 (en) * 1995-08-22 2005-02-15 The Regents Of The University Of California Methods for enhancing the production of interferon in cell culture
US5840565A (en) * 1995-08-22 1998-11-24 The Regents Of The University Of California Methods for enhancing the production of viral vaccines in PKR-deficient cell culture
US6740519B1 (en) * 1997-11-03 2004-05-25 Mount Sinai School Of Medicine Immortalized, homozygous stat1-deficient mammalian cell lines and their uses
SK288544B6 (sk) 1998-06-12 2018-03-05 Mount Sinai School Of Medicine Geneticky skonštruovaný oslabený chimérny vírus chrípky, vakcinačný prostriedok a farmaceutický prostriedok s jeho obsahom a ich použitie
US6762038B1 (en) * 1998-09-09 2004-07-13 The Cleveland Clinic Foundation Mutant cell lines and methods for producing enhanced levels of recombinant proteins
HK1048650A1 (zh) * 1999-06-15 2003-04-11 Genetrol Biotherapeutics 在细胞培养物中增强细胞激动素(cytokines)的方法
EP1067179A1 (en) * 1999-07-09 2001-01-10 Pierre Fabre Medicament Method to select attenuated paramyxoviridae useful for vaccines and therapeutics
WO2001018185A1 (en) * 1999-09-08 2001-03-15 Genetrol Biotherapeutics, Inc. High level cytokine production with enhanced cell viability
US20010031859A1 (en) * 1999-09-08 2001-10-18 Lau Allan S. High level cytokine production with enhanced cell viability
AU2001257001A1 (en) 2000-04-10 2001-10-23 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
IL136232A0 (en) * 2000-05-18 2001-05-20 Bar Ilan University Res Author Measurements of enzymatic activity in a single, individual cell in population
WO2002012477A2 (en) * 2000-08-04 2002-02-14 Chiron Corporation Enhanced replication of hcv rna
US20020150541A1 (en) * 2000-09-12 2002-10-17 Gene Trol Biotherapeutics, Inc. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
AU2001290855A1 (en) 2000-09-14 2002-03-26 Genetrol Biotherapeutics, Inc. Method and cell composition for screening compounds for anti-inflammatory activity
JP2005500816A (ja) * 2000-12-19 2005-01-13 ジーントロール バイオセラピューティクス， インコーポレイテッド サイトカイン産生を増加するための増大したｐｋｒ発現を有する細胞
DE10104094C1 (de) * 2001-01-31 2002-07-25 Angelika Vallbracht-Flehmig Verfahren zur Erhöhung der Virusvermehrung und Virusausbeute in Zellkulturen, durch Blockade der RNaseL-Aktivierung
EP1438385A1 (en) * 2001-10-25 2004-07-21 Bar-Ilan University Interactive transparent individual cells biochip processor
IL154677A0 (en) * 2003-02-27 2003-09-17 Univ Bar Ilan A method and apparatus for manipulating an individual cell
US20060240548A1 (en) * 2003-06-26 2006-10-26 Mordechai Deutsch Materials for constructing cell-chips, cell-chip covers, cell-chips coats, processed cell-chips and uses thereof
US7888110B2 (en) 2003-06-26 2011-02-15 Seng Enterprises Ltd. Pico liter well holding device and method of making the same
US9200245B2 (en) 2003-06-26 2015-12-01 Seng Enterprises Ltd. Multiwell plate
US8597597B2 (en) 2003-06-26 2013-12-03 Seng Enterprises Ltd. Picoliter well holding device and method of making the same
WO2005008626A1 (en) * 2003-07-11 2005-01-27 University Of North Carolina At Chapel Hill Methods and systems for controlling a computer using a video image and for combining the video image with a computer desktop
US20050064524A1 (en) * 2003-08-11 2005-03-24 Mordechai Deutsch Population of cells utilizable for substance detection and methods and devices using same
AU2004263037B2 (en) * 2003-08-11 2011-02-10 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Novel vaccine containing adjuvant capable of inducing mucosal immunity
BRPI0415771A (pt) 2003-10-23 2006-12-26 Illumigen Biosciences Inc detecção de mutações em um gene associado à resistência a infecção viral, oas1
NZ591879A (en) * 2003-10-23 2012-11-30 Kineta Two Llc Detection of mutations in a gene associated with resistance to viral infection, OAS1
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
WO2005074893A1 (en) * 2004-02-03 2005-08-18 Chemagis Ltd. Stable amorphous forms of montelukast sodium
CN1922308A (zh) * 2004-02-23 2007-02-28 克鲁塞尔荷兰公司 病毒纯化方法
BRPI0511776B1 (pt) 2004-06-01 2016-11-29 Sinai School Medicine vírus atenuado de influenza de suínos geneticamente engenheirado, formulação imunogênica, formulação farmacêutica, uso da formulação imunogênica, uso do vírus atenuado de influenza de suínos geneticamente engenheirado, uso da formulação farmacêutica e método para produzir uma vacina, uma formulação imunogênica ou uma formulação farmacêutica
WO2006003664A1 (en) * 2004-07-07 2006-01-12 Seng Enterprises Ltd. Method and device for identifying an image of a well in an image of a well-bearing component
US7403647B2 (en) * 2004-09-13 2008-07-22 Seng Enterprises Ltd. Method for identifying an image of a well in an image of a well-bearing component
US20080009051A1 (en) * 2004-08-25 2008-01-10 Seng Enterprises Ltd. Method and Device for Isolating Cells
US20060051369A1 (en) * 2004-08-27 2006-03-09 Taylor Deborah R ADAR1 antiviral pathway
US20080107683A1 (en) * 2004-11-30 2008-05-08 David Hone Bacterial Packaging Strains Useful for Generation and Production of Recombinant Double-Stranded RNA Nucleocapsids and Uses Thereof
ES2352344T3 (es) 2005-01-25 2011-02-17 Seng Enterprises Limited Dispositivo de microfluido para estudio de células.
EP1855713B1 (en) 2005-02-15 2016-04-27 Mount Sinai School of Medicine Genetically engineered equine influenza virus and uses thereof
ATE412737T1 (de) * 2005-04-11 2008-11-15 Crucell Holland Bv Virusreinigung mit ultrafiltration
UA95446C2 (ru) * 2005-05-04 2011-08-10 Іллюміджен Байосайєнсіз, Інк. Мутаци в генах oas1
DE102005034043B4 (de) * 2005-07-18 2019-12-12 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Gemisch, enthaltend L-Carnitin und Trehalulose, sowie Produkt enthaltend das Gemisch
US20070111309A1 (en) * 2005-10-04 2007-05-17 Daelli Marcelo G Vero cell line adapted to grow in suspension
US20070141555A1 (en) * 2005-10-11 2007-06-21 Mordechai Deutsch Current damper for the study of cells
WO2007052245A1 (en) 2005-11-03 2007-05-10 Seng Enterprises Ltd. Method and device for studying floating, living cells
US20070196333A1 (en) * 2006-02-23 2007-08-23 Fu-Yung Lin Composition comprising mixtures of IFN-alpha subtypes
US20060223999A1 (en) * 2006-05-10 2006-10-05 Chemagis Ltd. Process for preparing montelukast and precursors thereof
CN101675071B (zh) 2007-05-02 2014-06-18 Ambrx公司 经修饰干扰素β多肽和其用途
US9145540B1 (en) 2007-11-15 2015-09-29 Seng Enterprises Ltd. Device for the study of living cells
WO2009081409A2 (en) 2007-12-26 2009-07-02 Seng Enterprises Ltd. Device for the study of living cells
SG188143A1 (en) 2008-02-08 2013-03-28 Ambrx Inc Modified leptin polypeptides and their uses
EP2133358A1 (en) * 2008-06-10 2009-12-16 Universitätsklinikum Freiburg Rift valley fever virus-like particles and their use for immunization and as test system
RU2011107757A (ru) 2008-08-01 2012-09-10 Гамма Ваксинс Пти Лимитед (Au) Вакцины против гриппа
CN102257135B (zh) 2008-12-16 2017-06-09 纳米医疗公司 流感疫苗的生产
SG184833A1 (en) 2010-04-14 2012-11-29 Emd Millipore Corp Methods of producing high titer, high purity virus stocks and methods of use thereof
WO2012100302A1 (en) 2011-01-27 2012-08-02 Gamma Vaccines Pty Limited Combination vaccines
WO2013182498A1 (en) * 2012-06-04 2013-12-12 Novartis Ag Improved safety testing
BR112015018493A2 (pt) 2013-02-05 2017-08-22 Univ Georgia Linhagens celulares para produção de vírus e métodos de uso
KR20170122786A (ko) 2015-02-26 2017-11-06 베링거잉겔하임베트메디카게엠베하 2가 돼지 인플루엔자 바이러스 백신
WO2017070167A1 (en) * 2015-10-20 2017-04-27 The University Of North Carolina At Chapel Hill Methods and compositions for modified factor ix fusion proteins
KR102651055B1 (ko) 2016-03-24 2024-03-26 삼성디스플레이 주식회사 광학 필름 및 디스플레이 장치

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE33164E (en) * 1979-05-15 1990-02-13 Mobay Corporation Influenza vaccine production in liquid cell culture
JPS5754586A (en) * 1980-09-18 1982-04-01 Ajinomoto Co Inc Cell strain producing human interferon prolongably, its preparation, and preparation of human interferon using it
US4579821A (en) * 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
JPS58209993A (ja) * 1982-05-31 1983-12-07 Mochida Pharmaceut Co Ltd インタ−フエロンの産生方法
EP0097353B1 (en) * 1982-06-21 1990-08-16 The Wellcome Foundation Limited Improved process for interferon production
US4485038A (en) * 1982-10-19 1984-11-27 Health Research (Roswell Park Division) Method for the production and purification of human leukocyte interferon
US4966843A (en) * 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
US4745053A (en) * 1983-07-08 1988-05-17 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyojo Process for producing human interferon and method for assaying the interferon productivity of blood
JPS6062997A (ja) * 1983-09-17 1985-04-11 Mochida Pharmaceut Co Ltd インタ−フエロンの生産方法
US5196323A (en) * 1985-04-27 1993-03-23 Boehringer Ingelheim International Gmbh Process for preparing and purifying alpha-interferon
US4732683A (en) * 1986-12-02 1988-03-22 Biospectrum, Inc. Purification method for alpha interferon
ATE161041T1 (de) * 1989-08-25 1997-12-15 Chiron Corp Verfahren zur hcv-züchtung in zell-linien aus b- oder t-lymphozyten
US5149531A (en) * 1990-06-27 1992-09-22 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of using cold-adapted live influenza virus vaccine as an antiviral agent against influenza
JPH05260981A (ja) * 1992-03-02 1993-10-12 Massachusetts Inst Of Technol <Mit> ヘムに調節される真核細胞開始因子２αキナーゼをコードするＤＮＡ
FR2689520B1 (fr) * 1992-04-03 1996-07-19 Bio Merieux Procede et milieu de culture pour l'obtention de cellules infectees par un virus associe a la sclerose en plaques.
US5840565A (en) 1995-08-22 1998-11-24 The Regents Of The University Of California Methods for enhancing the production of viral vaccines in PKR-deficient cell culture

Also Published As

Publication number Publication date
AU6857696A (en) 1997-03-19
CA2229405C (en) 2004-03-02
US20010001290A1 (en) 2001-05-17
CA2229163C (en) 2011-04-05
US20040157310A1 (en) 2004-08-12
EP0846174A1 (en) 1998-06-10
US20010001709A1 (en) 2001-05-24
US6159712A (en) 2000-12-12
CN1161469C (zh) 2004-08-11
DE69634360T2 (de) 2005-12-29
EP0846160A1 (en) 1998-06-10
BR9610550A (pt) 1999-07-06
EP0846174A4 (en) 2003-02-05
MX9801423A (es) 1998-05-31
CA2229163A1 (en) 1997-03-06
EP0846160B1 (en) 2005-02-16
JP3432519B2 (ja) 2003-08-04
US6686190B2 (en) 2004-02-03
JPH11511324A (ja) 1999-10-05
EP0846160A4 (en) 2002-01-02
WO1997008324A1 (en) 1997-03-06
US6489144B1 (en) 2002-12-03
JPH11514344A (ja) 1999-12-07
US6673591B2 (en) 2004-01-06
AU6860896A (en) 1997-03-19
US7132271B2 (en) 2006-11-07
AU707130B2 (en) 1999-07-01
CA2229405A1 (en) 1997-03-06
ATE289348T1 (de) 2005-03-15
WO1997008292A1 (en) 1997-03-06
DE69634360D1 (de) 2005-03-24
US5840565A (en) 1998-11-24
CN1200148A (zh) 1998-11-25

Similar Documents

Publication Publication Date Title
US5840565A (en) Methods for enhancing the production of viral vaccines in PKR-deficient cell culture
JP2941804B2 (ja) 変性された生きている偽狂犬病ウイルスを含有する偽狂犬病ワクチン
Young et al. Paramyxoviridae use distinct virus-specific mechanisms to circumvent the interferon response
Pavlovic et al. Enhanced virus resistance of transgenic mice expressing the human MxA protein
Marcus et al. Interferon action: inhibition of vesicular stomatitis virus RNA synthesis induced by virion-bound polymerase
Beattie et al. Reversal of the interferon-sensitive phenotype of a vaccinia virus lacking E3L by expression of the reovirus S4 gene
Schmechel et al. Preferential translation of reovirus mRNA by a σ3-dependent mechanism
Anderson et al. The endoplasmic reticular heat shock protein gp96 is transcriptionally upregulated in interferon-treated cells.
Weck et al. Use of UV irradiation to identify the genetic information of vesicular stomatitis virus responsible for shutting off cellular RNA synthesis
Zhang et al. Expression of interferon-γ by a coronavirus defective-interfering RNA vector and its effect on viral replication, spread, and pathogenicity
JP2000503213A (ja) カポジ肉腫関連ウイルスのユニークな配列およびその使用
Bovolenta et al. Vesicular stomatitis virus infection induces a nuclear DNA-binding factor specific for the interferon-stimulated response element
Komatsu et al. Mechanisms of cytokine-mediated inhibition of viral replication
CN107858449A (zh) 一种犬干扰素α生物学活性检测方法
Azzam-Smoak et al. Interferon regulatory factor-1, interferon-β, and reovirus-induced myocarditis
Wagner Cytopathic effects of viruses: a general survey
MXPA98001423A (en) Methods to improve the production of viral vaccines in cellular cultivation through interruption suppression
Saito Enhancement of the interferon‐induced double‐stranded RNA‐dependent protein kinase activity by Sindbis virus infection and heat‐shock stress
Sherry The role of interferon regulatory factors in the cardiac response to viral infection
Bruns et al. Host cell-dependent homologous interference in lymphocytic choriomeningitis virus infection
CN119548519B (zh) 抑制lnc-ALOX12的物质在制备流感病毒抑制剂中的应用
MIZUTANI et al. Inhibition of mouse hepatitis virus multiplication by an oligonucleotide complementary to the leader RNA
Marcus Interferon induction by viruses
US20070036787A1 (en) Insulin-induced gene as therapeutic target in diabetes
Teague LUBAC is required for the RIG-I mediated antiviral response

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070320

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070619

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090210

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090219

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120227

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130227

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130227

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140227

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term